| Not Yet Recruiting | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors Solid Tumors | Phase 1 / Phase 2 | 2026-04-30 |
| Not Yet Recruiting | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Colorectal (Colon or Rectal) Cancer | Phase 2 / Phase 3 | 2026-04-30 |
| Not Yet Recruiting | Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease CTD-ILD | Phase 3 | 2026-04-20 |
| Not Yet Recruiting | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamou Non-Small Cell Lung Cancer | Phase 3 | 2026-03-31 |
| Recruiting | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) Myasthenia Gravis, Ocular | Phase 3 | 2026-01-13 |
| Recruiting | A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Tras Gastric Carcinoma | Phase 3 | 2026-01-01 |
| Recruiting | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors Solid Tumors | Phase 1 / Phase 2 | 2025-08-11 |
| Recruiting | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combin Non-Small Cell Lung Cancer | Phase 2 | 2025-06-30 |
| Not Yet Recruiting | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Che Gastric Carcinoma | Phase 3 | 2025-05-15 |
| Active Not Recruiting | A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC Non-Small Cell Lung Cancer | Phase 1 | 2025-03-13 |
| Recruiting | Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low B Breast Cancer | Phase 2 | 2025-02-10 |
| Withdrawn | Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Loc Breast Neoplasms | Phase 2 | 2024-12-20 |
| Recruiting | A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-d Healthy | Phase 1 | 2024-08-05 |
| Recruiting | To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in P High-risk Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | 2024-06-14 |
| Recruiting | To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Breast Cancer | Phase 2 | 2024-04-29 |
| Recruiting | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castrat Castration-resistant Prostate Cancer | Phase 2 | 2024-04-08 |
| Unknown | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Muta Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2024-04-01 |
| Recruiting | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Ade Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | 2024-02-22 |
| Completed | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | Phase 2 | 2024-01-19 |
| Recruiting | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Cervical Cancer | Phase 2 | 2024-01-11 |
| Recruiting | DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Ca Breast Cancer | Phase 2 | 2023-11-28 |
| Recruiting | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcin Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2023-11-27 |
| Recruiting | A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or M Solid Tumor | Phase 1 / Phase 2 | 2023-09-14 |
| Recruiting | RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC NSCLC | Phase 1 / Phase 2 | 2023-09-07 |
| Active Not Recruiting | A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer Gastric Cancer | Phase 2 / Phase 3 | 2023-08-04 |
| Recruiting | A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid T Advanced Solid Tumor | Phase 1 / Phase 2 | 2023-08-03 |
| Recruiting | Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressin Breast Cancer | Phase 2 | 2023-07-27 |
| Recruiting | A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours Advanced Solid Tumours | Phase 1 / Phase 2 | 2023-07-19 |
| Recruiting | RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression Solid Tumor | Phase 1 | 2023-06-29 |
| Recruiting | Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema Diabetic Macular Edema | Phase 3 | 2023-06-08 |
| Recruiting | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects NMIBC | Phase 2 | 2023-06-08 |
| Active Not Recruiting | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma | Phase 1 | 2023-06-05 |
| Completed | A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus Systemic Lupus Erythematosus | Phase 1 | 2023-05-25 |
| Active Not Recruiting | A Study of Telitacicept for IgA Nephropathy (TELIGAN) Primary IgA Nephropathy | Phase 3 | 2023-04-28 |
| Recruiting | A Study of Telitacicept in Lupus Nephritis Lupus Nephritis | Phase 2 | 2023-04-17 |
| Completed | A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome Primary Sjogren's Syndrome | Phase 3 | 2023-04-06 |
| Completed | Study of Telitacicept in Generalized Myasthenia Gravis Myasthenia Gravis, Generalized | Phase 3 | 2023-03-28 |
| Unknown | Efficacy and Safety of RC28-E Versus Aflibercept Wet Age-related Macular Degeneration | Phase 3 | 2023-03-14 |
| Completed | A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours Advanced Solid Tumours | Phase 1 / Phase 2 | 2023-01-30 |
| Completed | A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor Digestive Cancer | Phase 2 | 2022-11-11 |
| Unknown | To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined Gastric Cancer | Phase 1 | 2022-09-28 |
| Recruiting | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma Urothelial Carcinoma, HER2-expressing | Phase 3 | 2022-06-14 |
| Unknown | A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer Muscle Invasive Bladder Carcinoma | Phase 2 | 2022-05-26 |
| Completed | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus Systemic Lupus Erythematosus | Phase 1 | 2022-05-11 |
| Unknown | A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) Melanoma, Stage II, HER2-positive, Advanced Melanoma | Phase 2 | 2022-04-19 |
| Recruiting | A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2022-03-03 |
| Unknown | A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies Gynecological Malignancy | Phase 2 | 2021-12-21 |
| Completed | A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours Unresectable Solid Tumor, Metastatic Solid Tumor, Locally Advanced Solid Tumor | Phase 1 | 2021-11-29 |
| Terminated | A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy IgA Nephropathy | Phase 2 | 2021-11-04 |
| Unknown | Evaluation of RC28-E Injection in Diabetic Retinopathy Diabetic Retinopathy | Phase 2 | 2021-05-25 |
| Terminated | RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial Multiple Sclerosis, Relapsing-Remitting | Phase 2 | 2021-05-13 |
| Unknown | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | Phase 3 | 2021-03-24 |
| Completed | Evaluation of RC28-E Injection in Diabetic Macular Edema Diabetic Macular Edema | Phase 2 | 2021-03-17 |
| Completed | A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors Solid Tumor | Phase 1 | 2021-03-10 |
| Unknown | A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of H Breast Cancer | Phase 3 | 2020-09-29 |
| Unknown | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer Biliary Tract Cancer | Phase 2 | 2020-08-24 |
| Completed | A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibo Systemic Myasthenia Gravis | Phase 2 | 2020-07-07 |
| Completed | Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration Wet Age-Related Macular Degeneration | Phase 1 / Phase 2 | 2020-04-15 |
| Completed | A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2020-04-14 |
| Completed | A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy Primary IgA Nephropathy | Phase 2 | 2020-04-13 |
| Unknown | A Study of RC98 in Subjects With Advanced Malignant Solid Tumors Solid Tumors | Phase 1 | 2020-03-15 |
| Completed | A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome Primary Sjögren's Syndrome | Phase 2 | 2019-11-21 |
| Completed | Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Eryt Systemic Lupus Erythematosus | Phase 3 | 2019-10-16 |
| Completed | A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects Healthy | Phase 1 | 2019-09-17 |
| Completed | A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer Urothelial Carcinoma | Phase 2 | 2019-08-19 |
| Completed | A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subje Urothelial Carcinoma | Phase 2 | 2019-01-07 |
| Completed | Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With W Neovascular Age-related Macular Degeneration | Phase 1 | 2019-01-07 |
| Completed | A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Non Small Cell Lung Cancer | Phase 1 / Phase 2 | 2018-09-26 |
| Completed | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2 Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | Phase 2 | 2018-07-10 |
| Unknown | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Breast Neoplasms, Breast Diseases, Capecitabine | Phase 2 / Phase 3 | 2018-04-24 |
| Terminated | A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spect Neuromyelitis Optica Spectrum Disorders | Phase 3 | 2018-01-29 |
| Completed | A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer Urothelial Carcinoma, Advanced Cancer | Phase 2 | 2017-12-28 |
| Completed | A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequat Moderate and Severe RheumatoId Arthritis | Phase 3 | 2017-03-29 |
| Completed | A Study of RC48-ADC in Subjects With Advanced Breast Cancer Advanced Breast Cancer | Phase 1 / Phase 2 | 2016-12-23 |
| Completed | A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors Solid Tumors | Phase 1 | 2016-03-01 |
| Completed | Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors Solid Tumors | Phase 1 | 2015-12-14 |
| Completed | Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) Systemic Lupus Erythematosus | Phase 2 | 2015-12-01 |
| Terminated | A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequat Moderate and Severe Rheumatoid Arthritis | Phase 2 | 2015-10-01 |